A panelist discusses how the DORA class of medications offers a novel approach to treating insomnia by selectively targeting orexin receptors to regulate sleep-wake cycles.
EP. 1: Managing Insomnia: History, Comorbidities, and Clinical Insight
May 16th 2025A panelist discusses how effective management of chronic insomnia requires a multifactorial, individualized approach that combines thorough patient evaluation with both behavioral strategies and targeted pharmacologic treatments.
EP. 2: Building Consistency in Long-Term Management of Insomnia
May 16th 2025A panelist discusses how long-term success in treating chronic insomnia depends on patient adherence, realistic expectations, and a strong therapeutic relationship that supports consistent behavioral changes and ongoing treatment adjustments.
EP. 3: Overview of DORA Class Medications for the Treatment of Insomnia
May 23rd 2025A panelist discusses how dual orexin receptor antagonists (DORAs) provide a novel and balanced approach to treating insomnia by targeting orexin receptors to reduce wakefulness without causing the broad central nervous system suppression seen with traditional sleep aids.
EP. 4: Counseling About Insomnia Medications Q6
May 23rd 2025A panelist discusses how managing chronic insomnia often requires tailored treatments like dual orexin receptor antagonists (DORAs), which offer long-term benefits for sleep maintenance without the risk of tolerance or rebound insomnia, while emphasizing patient counseling and realistic expectations for gradual improvement.
EP. 5: From Trials to Treatment: Understanding the Treatment Profile of Daridorexant
May 30th 2025A panelist discusses how dual orexin receptor antagonists (DORAs) are effective for treating both sleep initiation and maintenance insomnia, with a generally favorable adverse effect profile, though patients should be informed about potential risks like parasomnia-like behaviors, and the importance of patience and adherence for optimal results.
EP. 6: Why Choose a DORA? Clinical Considerations for Patients With Insomnia
May 30th 2025A panelist discusses how clinicians choose between sleep aids like dual orexin receptor antagonists (DORAs) and other medications based on patient comorbidities, chronicity of insomnia, and adverse effect profiles, with DORAs offering a safer, long-term solution for patients with chronic insomnia and sleep maintenance issues.
EP. 7: Clinical Perspectives on DORAs for Insomnia Management
June 6th 2025A panelist discusses how dual orexin receptor antagonists (DORAs) are considered a first-line treatment for chronic insomnia, particularly for sleep maintenance issues, due to their superior tolerability, lack of withdrawal symptoms, and positive impact on daytime functioning.
EP. 8: Daridorexant and Next-Day Function: What Patients Are Reporting
June 6th 2025A panelist discusses how dual orexin receptor antagonists (DORAs) are ideal for patients with chronic insomnia who require long-term sleep support, emphasizing their safety, tolerability, and effectiveness, while cautioning against use in patients with narcolepsy, parasomnia history, or severe kidney or liver disease.
EP. 9: Looking at the Future of Insomnia Management
June 6th 2025A panelist discusses how dual orexin receptor antagonists (DORAs), particularly daridorexant, are poised to become a first-line treatment for chronic insomnia, especially for elderly patients, due to their safety, tolerability, and lack of withdrawal symptoms, while highlighting the importance of patient education and regular follow-up for optimal results.
EP. 10: Chronic Insomnia Diagnosis and Management
June 20th 2025A panelist discusses how managing chronic insomnia requires a comprehensive, multifaceted approach that integrates behavioral interventions like CBT-I with pharmacologic treatments, guided by thorough sleep assessments and tailored to each patient’s specific sleep patterns and comorbid conditions.